FDA Drugs (New Approvals & NDA)Original article
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
Regulatoryapprovedtirzepatide injectionPositive
AI Analysis
Summary
The FDA has determined that the tirzepatide injection shortage, which began in 2022 due to increased demand, has been resolved and the national GLP-1 supply is stabilizing. The agency has clarified policies for compounders as part of addressing the supply situation.
Outcome Details
FDA determined shortage of tirzepatide injection has been resolved
Importance:4/10
Sentiment:
0.60
GLP-1TirzepatideSupply ShortageFDARegulatory
Related Companies
Read the original article
Published by FDA Drugs (New Approvals & NDA) on September 16, 2026 6:03 PM